Please assess the completion status of the following clinical trial:

Trial Title: Internal Radiation Therapy in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of hepatocellular carcinoma~  * Not amenable to surgical resection or immediate liver transplantation~    * Destaging of tumor prior to surgical resection or transplantation allowed~* Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1 dimension (longest diameter to be recorded) ≥ 10 mm by contrasted CT scan~  * No equivocal, nonmeasurable, or nonevaluable liver cancer~* No more than 75% replacement of normal liver by tumor~* Cancer of the Liver Italian Program (CLIP) stage 1-3 disease~* No extra-hepatic metastases as determined by CT scan or MRI~Exclusion Criteria:~* Life expectancy ≥ 3 months~* Karnofsky performance status 50-100%~* Creatinine ≤ 1.5 mg/dL~* Bilirubin ≤ 2.0 mg/dL~* Albumin ≥ 3 g/dL~* Granulocyte count ≥ 1,500/mm³~* Platelet count ≥ 65,000/mm³~* INR ≤ 1.4~* Hemoglobin \> 9 g/dL~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 3 months after completion of study treatment~* No nonmalignant disease that would render the patient ineligible for treatment according to this protocol~* No hepatic arterial anatomy that would prevent the administration of study drug into the liver~* Less than 20% arteriovenous lung shunting on a technetium 99m-labeled macroaggregated albumin nuclear scan~* No other malignancy within the past 5 years except for cured basal cell carcinoma of the skin or cured carcinoma in situ of the uterine cervix~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* More than 90 days since prior surgery, chemotherapy, or locally ablative technique for the liver cancer~* More than 4 weeks since prior and no other concurrent investigational drug or agent/procedure (i.e., participation in another trial)~* No prior radiotherapy to the upper abdomen that included the liver in the treatment field~* No capecitabine within 8 weeks before or after study treatment~* No other anticancer treatment (except surgical resection) for liver cancer during and for 3 months after completion of study treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- SIR-SPHERES (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).